Research Progress and outlook of drugs for the treatment for Alzheimer’s disease
DOI:
https://doi.org/10.61173/4z762m76Keywords:
Alzheimer’s disease, cholinesterase inhibi-tors, research progressAbstract
As the global population is aging at an increasingly rapid rate, AD has become an important disease affecting the health of the elderly in today’s world and has attracted the attention of many experts. AD is a neurodegenerative disease characterized by progressive cognitive decline, manifested by deterioration of memory, learning and daily living skills. If the disease is not controlled, patients will develop dementia symptoms. Although AD cannot be completely cured at this time, a combination of pharmacologic and non-pharmacologic treatments are currently available to alleviate symptoms. Pharmacological treatment may include cholinesterase inhibitors (ChEIs) and NMDA receptor antagonists. Non-pharmacological treatments include psychotherapy, cognitive training and life skills exercise. This paper now reviews the mechanisms, applications and side effects of the corresponding drugs that have been used to treat AD, and analyzes the emerging AD treatments, with a view to providing a reference for the research of new AD therapeutic drugs.
References
[1] Se Thoe, E., Fauzi, A., Tang, Y. Q., Chamyuang, S., & Chia, A. Y. Y. A review on advances of treatment modalities for Alzheimer’s disease. Life Sciences, 2021, 276: 119129. Dean&Francis ISSN 2959-409X
[2] Breijyeh, Z., & Karaman, R. Comprehensive review on Alzheimer’s disease: causes and treatment. Molecules (Basel, Switzerland), 2020, 25(24): 5789.
[3] Cummings, J., Apostolova, L., Rabinovici, G. D., Atri, A., Aisen, P., Greenberg, S., Hendrix, S., Selkoe, D., Weiner, M., Petersen, R. C., & Salloway, S. Lecanemab: appropriate use recommendations. The Journal of Prevention of Alzheimer’s Disease, 2023, 10(3): 362–377.
[4] Marucci, G., Buccioni, M., Ben, D. D., Lambertucci, C., Volpini, R., & Amenta, F. Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease. Neuropharmacology, 2021, 190: 108352.
[5] Haake, A., Nguyen, K., Friedman, L., Chakkamparambil, B., & Grossberg, G. T. An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease. Expert Opinion on Drug Safety, 2020, 19(2): 147–157.
[6] Kabir, M. T., Uddin, M. S., Begum, M. M., Thangapandiyan, S., Rahman, M. S., Aleya, L., Mathew, B., Ahmed, M., Barreto, G. E., & Ashraf, G. M. Cholinesterase inhibitors for Alzheimer’s disease: multitargeting strategy based on anti-Alzheimer’s drugs repositioning. Current Pharmaceutical Design, 2019, 25(33): 3519–3535.
[7] M e h t a , M . , A d e m , A . , & S a b b a g h , M . N e w acetylcholinesterase inhibitors for Alzheimer’s disease. International Journal of Alzheimer’s Disease, 2012, 728983.
[8] Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., & Friedhoff, L. T. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology, 1998, 50(1): 136–145.
[9] Parsons, C. G., Danysz, W., & Quack, G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data. Neuropharmacology, 1999, 38(6): 735–767.
[10] Nikayin, S., Murphy, E., Krystal, J. H., & Wilkinson, S. T. Long-term safety of ketamine and esketamine in treatment of depression. Expert Opinion on Drug Safety, 2022, 21(6): 777– 787.
[11] Wisniewski, T., & Goñi, F. Immunotherapy for Alzheimer’s disease. Biochemical Pharmacology, 2014, 88(4): 499-507.
[12] Cullen, N. C., Novak, P., Tosun, D., Kovacech, B., Hanes, J., Kontsekova, E., Fresser, M., Ropele, S., Feldman, H. H., Schmidt, R., Winblad, B., & Zilka, N. Efficacy assessment of an active tau immunotherapy in Alzheimer’s disease patients with amyloid and tau pathology: a post hoc analysis of the “ADAMANT” randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial. EBioMedicine, 2024, 99: 104923.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
